Inspire Medical Systems (NYSE:INSP) Stock Rating Raised to Strong Sell at Barclays

Barclays upgraded shares of Inspire Medical Systems (NYSE:INSP) to a strong sell rating in a report published on Tuesday morning,Zacks reports.

INSP has been the subject of a number of other research reports. Stifel Nicolaus lifted their price target on Inspire Medical Systems from $75.00 to $80.00 and gave the stock a “buy” rating in a report on Friday, September 11th. Robert W. Baird upped their price objective on Inspire Medical Systems from $54.00 to $59.00 and gave the company a “neutral” rating in a research note on Tuesday, August 4th. JPMorgan Chase & Co. raised their price objective on Inspire Medical Systems from $54.00 to $60.00 and gave the company a “neutral” rating in a research report on Tuesday, August 4th. Royal Bank Of Canada lifted their target price on Inspire Medical Systems from $60.00 to $75.00 and gave the stock a “sector perform” rating in a research note on Thursday, October 1st. Finally, Evercore set a $54.00 price target on Inspire Medical Systems in a research note on Tuesday, August 4th. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, twelve have issued a Hold rating and four have issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $67.29.

Inspire Medical Systems Trading Down 1.4%

NYSE INSP opened at $66.50 on Tuesday. The firm has a market capitalization of $1.92 billion, a P/E ratio of 14.39, a price-to-earnings-growth ratio of 5.10 and a beta of 0.73. The firm’s fifty day moving average price is $64.86 and its two-hundred day moving average price is $54.06. Inspire Medical Systems has a 1 year low of $38.91 and a 1 year high of $147.03.

Inspire Medical Systems (NYSE:INSP) last announced its quarterly earnings data on Monday, August 3rd. The company reported $0.14 EPS for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.38. The company had revenue of $200.58 million during the quarter, compared to the consensus estimate of $194.72 million. Inspire Medical Systems had a net margin of 15.03% and a return on equity of 8.64%. The company’s quarterly revenue was down 7.6% on a year-over-year basis. During the same quarter last year, the firm posted $0.45 EPS. Inspire Medical Systems has set its FY 2026 guidance at 1.050-1.450 EPS. On average, research analysts anticipate that Inspire Medical Systems will post 1.24 EPS for the current fiscal year.

Insider Buying and Selling at Inspire Medical Systems

In other news, insider Jason Kelly sold 963 shares of the stock in a transaction that occurred on Friday, August 7th. The stock was sold at an average price of $59.55, for a total transaction of $57,346.65. Following the transaction, the insider owned 18,985 shares in the company, valued at approximately $1,130,556.75. This trade represents a 4.83% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 2.20% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. WINTON GROUP Ltd grew its stake in shares of Inspire Medical Systems by 790.8% during the second quarter. WINTON GROUP Ltd now owns 37,412 shares of the company’s stock worth $1,669,000 after buying an additional 33,212 shares during the last quarter. Legal & General Group Plc bought a new stake in Inspire Medical Systems during the 2nd quarter worth $2,732,000. Alberta Investment Management Corp acquired a new position in Inspire Medical Systems in the 2nd quarter worth about $5,483,000. GSA Capital Partners LLP acquired a new position in shares of Inspire Medical Systems in the second quarter valued at approximately $820,000. Finally, Empowered Funds LLC acquired a new position in Inspire Medical Systems in the 2nd quarter valued at approximately $2,260,000. Institutional investors own 94.91% of the company’s stock.

Inspire Medical Systems Company Profile

Inspire Medical Systems, Inc is a medical technology company focused on developing and commercializing treatments for obstructive sleep apnea (OSA), a condition in which the upper airway repeatedly becomes blocked during sleep. The company’s primary product is the Inspire therapy system, an implantable device designed for certain adults with moderate to severe OSA who are unable to use or obtain consistent benefits from continuous positive airway pressure (CPAP) therapy.

The Inspire system uses an implantable pulse generator, a stimulation lead and a sensing lead.